ClinicalTrials.gg
CompletedNCT07946978Updated Nov 18, 2026

A Clinical Trial to Evaluate the Effects of a Supplement on Appetite, Gut Health, and Blood Sugar

An interventional study of Etta Vita GLP-1 Supplement Intervention in Overweight, Obesity and Appetite Dysregulation, sponsored by Etta Vita. Completed at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Etta Vita · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2026, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
21 Years to 60 Years
Sex
All
01

Study summary

This study evaluates the effects of the Etta Vita GLP-1 supplement on appetite, gut health, and blood sugar over a 12-week period. Thirty participants with a BMI of 25 or greater and experiencing at least two of the following issues - food cravings, poor appetite control, irregular bowel movements, bloating, or gut issues - will use the test product daily.

The trial is a single-arm, open-label study in which all participants take two capsules of the supplement each morning, no more than 15 minutes before their first meal. Participants complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and attend their local clinic for blood tests (HbA1c, Glucose, and Leptin) at Baseline and Week 12.

02

Conditions studied

  • Overweight
  • Obesity
  • Appetite Dysregulation
  • Blood Sugar
  • Gut Health

Browse trials for

03

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 30 is below the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

This is the only study on the registry with Etta Vita as lead sponsor.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be male or female
  • greater than or equal to 25
  • Be aged 21-60
  • Anyone experiencing issues regarding any two of the following over the past four weeks: food cravings, poor appetite control, irregular bowel movements, bloating, or gut issues
  • If taking any products, prescription medications, or supplements that target appetite, blood sugar, and gut health, has been doing so consistently for at least three months, and is willing to maintain this routine for the duration of the test period
  • Anyone willing to maintain their current sleep schedule and activity level for the duration of the study
  • Anyone who considers themselves in good general health
  • Resides in the United States

Exclusion criteria

Exclusion Criteria:

  • Anyone with any chronic health conditions that could impact participation in this study, such as cancer, mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period
  • Anyone who drinks heavily (i.e. 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men)
  • Anyone with a known history of severe digestive disorders like acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), ulcerative colitis (UC), celiac disease, Crohn's disease, or gastrointestinal tract surgeries
  • Anyone currently taking GLP-1 receptor agonist medications
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
  • Anyone diagnosed with renal or hepatic disease
  • Anyone diagnosed with type 1 or type 2 diabetes
  • Anyone unwilling to follow the study protocol
  • Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Etta Vita GLP-1 Supplement

    Dietary Supplement: Etta Vita GLP-1 Supplement Intervention

Interventions

  • Dietary supplementEtta Vita GLP-1 Supplement Intervention

    All 30 participants receive the Etta Vita GLP-1 supplement (two capsules taken orally each morning, no more than 15 minutes before the first meal of the day) for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Blood Glucose via blood test

    Mean change in fasting glucose (lab code 001032) from baseline to Week 12, assessed via blood test

    Time frame: Baseline to Week 12

  2. Change in HbA1c via blood test

    Mean change in glycated hemoglobin (HbA1c, lab code 001453) from baseline to Week 12, assessed via blood test

    Time frame: Baseline to Week 12

  3. Change in Leptin via blood test

    Mean change in serum leptin level (lab code 146712) from baseline to Week 12, assessed via blood test

    Time frame: Baseline to Week 12

  4. Change in Appetite via self-reported questionnaire

    Mean change in self-reported appetite from baseline, assessed via self-reported questionnaire

    Time frame: Baseline, Week 4, Week 8, and Week 12

Secondary outcomes

  1. Change in Self-Reported Food Cravings via self-reported questionnaire

    Mean change in self-reported food cravings from baseline, assessed via self-reported questionnaire

    Time frame: Baseline, Week 4, Week 8, and Week 12

  2. Change in Self-Reported Bowel Movements via self-reported questionnaire

    Mean change in self-reported bowel movement regularity from baseline, assessed via self-reported questionnaire

    Time frame: Baseline, Week 4, Week 8, and Week 12

  3. Change in Self-Reported Bloating via self-reported questionnaire

    Mean change in self-reported bloating from baseline, assessed via self-reported questionnaire

    Time frame: Baseline, Week 4, Week 8, and Week 12

  4. Change in Self-Reported Gut Health via self-reported questionnaire

    Mean change in self-reported gut issues from baseline, assessed via self-reported questionnaire

    Time frame: Baseline, Week 4, Week 8, and Week 12

  5. Participant Perception of Product Effects on Blood Sugar via self-reported questionnaire

    Self-reported perception of the supplement's effects on blood sugar, assessed via self-reported questionnaire

    Time frame: Baseline, Week 4, Week 8, and Week 12

07

Study locations

1 site
  • Citruslabs
    Las Vegas, Nevada 89101, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Aug 2026, 4 months.

Of 164 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 4 months is below that.

Counting every sponsor, half of 3,858 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Apr 1, 2026
Primary completionActual
Aug 30, 2026
CompletionActual
Aug 30, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946978
Lead sponsor
Etta Vita
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Apr 1, 2026
Primary completion
Aug 30, 2026
Completion
Aug 30, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion